Results 151 to 160 of about 2,536,972 (251)
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Glottoplasty for vocal feminization in transgender women: position paper of the Brazilian Academy of Laryngology and Voice (ABLV). [PDF]
Aires MM +9 more
europepmc +1 more source
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi +2 more
wiley +1 more source
COVID-19 vaccine acceptance and recommendation among health workers in nine countries: a pooled analysis of survey data from 2023 to 2024. [PDF]
Carlton JG +23 more
europepmc +1 more source
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones +3 more
wiley +1 more source
RioCC: Efficient and Accurate Class-Level Code Recommendation Based on Deep Code Clone Detection. [PDF]
Gao H, Guo C, Yang H.
europepmc +1 more source
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt +5 more
wiley +1 more source
Posterior a la publicación de la última guía del III Panel sobre Tratamiento en Adultos del Programa Nacional sobre Educación en Colesterol de Los Estados Unidos de Norte-América (ATPIII-NCEP) -año 2004- (1), se publicaron varios estudios clínicos y meta-
Alonso Merchán
doaj

